| Pharmaceutical Information |
| Drug Name |
Clascoterone |
| Drug ID |
BADD_D02543 |
| Description |
Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity.[A218771] By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and inflammatory pathways.[A218846] In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older.[L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766] |
| Indications and Usage |
Clascoterone is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.[L15626] |
| Marketing Status |
approved; investigational |
| ATC Code |
D10AX06 |
| DrugBank ID |
DB12499
|
| KEGG ID |
D11451
|
| MeSH ID |
C496269
|
| PubChem ID |
11750009
|
| TTD Drug ID |
D08TEJ
|
| NDC Product Code |
58175-0650; 73309-359; 47335-994; 82891-011 |
| UNII |
XN7MM8XG2M
|
| Synonyms |
Clascoterone | CB-03-01 | cortexolone 17alpha-propionate | winlevi |
|
| Chemical Information |
| Molecular Formula |
C24H34O5 |
| CAS Registry Number |
19608-29-8 |
| SMILES |
CCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(=O)CO |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
